Home › Multiple Myeloma › Texas › Lubbock
Multiple Myeloma clinical trials in Lubbock, TX
4 studies for Multiple Myeloma are looking for participants at sites in and around Lubbock (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
RecruitingPhase 3
- Joe Arrington Cancer Research and Treatment Center, Lubbock
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
RecruitingPhase 3
- Joe Arrington Cancer Research Treatment Center, Lubbock
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
RecruitingPhase 4
- Texas Tech University Health Science Center School of Medicine, Lubbock
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 3
- Joe Arrington Cancer Research Treatment Center, Lubbock
About Multiple Myeloma
Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. Discover symptoms, diagnostic tests, and treatments for myeloma.
More about Multiple Myeloma on MedlinePlus
Multiple Myeloma trials in other cities
- New York City, NY59 studies
- Boston, MA45 studies
- Atlanta, GA42 studies
- Houston, TX39 studies
- Durham, NC36 studies
- Nashville, TN31 studies
- Denver, CO26 studies
- St. Louis, MO26 studies
- Rochester, MN25 studies
- Columbus, OH25 studies
- Chicago, IL24 studies
- Milwaukee, WI23 studies
Other studies in Lubbock
- Ulcerative Colitis9 studies
- Crohn's Disease9 studies
- Breast Cancer6 studies
- Non-Small Cell Lung Cancer5 studies
- Inflammatory Bowel Disease3 studies
- Burkitt Lymphoma3 studies
- Neuroblastoma3 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.